Among the half a million childhood cancer survivors alive in the US today, the most commonly reported non-
cancer severe, life-threatening, or fatal chronic condition is cardiovascular disease (CVD) . It is the leading non-
cancer cause of premature death in this population. Heart radiation and anthracycline exposure have been
associated with a variety of CVD outcomes including cardiomyopathy, coronary artery disease (CAD), and
heart valve disease. Investigations of radiation therapy (RT)-related CVD have typically established
associations based solely on whole heart dose metrics; thus, overlooking the heterogeneity of the organ and its
substructures. Our team was the first to report data demonstrating substructure-level dose response of CVD
risk in childhood cancer survivors. Despite establishing distinct radiosentivities, cardiac substructure dose
constraints are not commonly incorporated into RT treatment planning due to the lack o f validated risk
prediction models, thus, missing opportunities to prospectively optimize RT planning and retrospectively
personalize risk-counseling and long-term cardiovascular surveillance in current and future cancer survivors.
The goal of the proposed project is to develop and validate novel CVD risk prediction models that incorporate
cardiac substructure doses. Further, we propose to develop tools to clinically translate these models into
effective personalized treatment paradigms with prospective and retrospective applications for care providers
to reduce CVD risk. We will: (1) develop and validate risk prediction models for cardiomyopathy, CAD, and
heart valve disease incorporating cardiac RT substructure doses, adjusting for demographics and
chemotherapy exposures; and (2) integrate CVD risk prediction models into commercial RT treatment planning
systems and web-based applications, and establish their use via in-silico studies of contemporary patients
treated with RT.
This will be the first investigation to use the unique radiosensitivity of different cardiac substructures as the
foundation for models that can predict the risk of specific types of CVD in children newly diagnosed with cancer
as well as among long-term survivors. Incorporating the substructure doses into prediction models will
significantly advance clinical care for both prospective RT treatment planning and retrospect ive risk
assessments. Prospectively, late CVD risk could be decreased in future survivors by optimizing delivery of
chest-directed RT with cardiac substructure dose constraints and selecting the plan that confers the lowest
risk, while maintaining optimal clinical target volume coverage. Retrospectively post treatment, the clinical team
can provide evidence-based personalized risk mitigation counseling, based on individualized risk profiles
determined from delivered cardiac substructure doses adjusted for chemotherapy exposures and
demographics. Successful execution of the proposed project has the potential to transform clinical practice for
treatment of childhood and adolescent patients with cancer.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.